{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T05:00:43Z","timestamp":1794200443062,"version":"4.8.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T00:00:00Z","timestamp":1746144000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T00:00:00Z","timestamp":1746144000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Immunol"],"DOI":"10.1186\/s12865-025-00714-7","type":"journal-article","created":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T12:27:40Z","timestamp":1746188860000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["A comparative analysis of drug-induced kidney injury adverse reactions between cyclosporine and tacrolimus based on the FAERS database"],"prefix":"10.1186","volume":"26","author":[{"given":"Min","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanggang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueliang","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,2]]},"reference":[{"issue":"7","key":"714_CR1","doi-asserted-by":"publisher","first-page":"559","DOI":"10.2174\/1389200218666171108154419","volume":"19","author":"H Wu","year":"2018","unstructured":"Wu H, Huang J, Drug-Induced, Nephrotoxicity. Pathogenic mechanisms, biomarkers and prevention strategies. Curr Drug Metab. 2018;19(7):559\u201367.","journal-title":"Curr Drug Metab"},{"issue":"12","key":"714_CR2","doi-asserted-by":"publisher","first-page":"3397","DOI":"10.1007\/s00204-019-02598-0","volume":"93","author":"J Faria","year":"2019","unstructured":"Faria J, Ahmed S, Gerritsen KGF, et al. Kidney-based in vitro models for drug-induced toxicity testing. Arch Toxicol. 2019;93(12):3397\u2013418.","journal-title":"Arch Toxicol"},{"issue":"3","key":"714_CR3","doi-asserted-by":"publisher","first-page":"268","DOI":"10.4062\/biomolther.2012.20.3.268","volume":"20","author":"SY Kim","year":"2012","unstructured":"Kim SY, Moon A. Drug-induced nephrotoxicity and its biomarkers. Biomol Ther (Seoul). 2012;20(3):268\u201372.","journal-title":"Biomol Ther (Seoul)"},{"issue":"8","key":"714_CR4","doi-asserted-by":"publisher","first-page":"e11447","DOI":"10.5812\/hepatmon.11447","volume":"13","author":"Z Mostafavi-Pour","year":"2013","unstructured":"Mostafavi-Pour Z, Khademi F, Zal F, et al. In vitro analysis of CsA-Induced hepatotoxicity in HepG2 cell line: oxidative stress and \u03912 and \u03921 integrin subunits expression. Hepat Mon. 2013;13(8):e11447.","journal-title":"Hepat Mon"},{"issue":"6","key":"714_CR5","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1038\/ki.1992.231","volume":"41","author":"DL Ciresi","year":"1992","unstructured":"Ciresi DL, Lloyd MA, Sandberg SM, et al. The sodium retaining effects of cyclosporine. Kidney Int. 1992;41(6):1599\u2013605.","journal-title":"Kidney Int"},{"key":"714_CR6","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/j.fct.2018.06.054","volume":"118","author":"Q Wu","year":"2018","unstructured":"Wu Q, Wang X, Nepovimova E, et al. Mechanism of cyclosporine A nephrotoxicity: oxidative stress, autophagy, and signalings. Food Chem Toxicol. 2018;118:889\u2013907.","journal-title":"Food Chem Toxicol"},{"key":"714_CR7","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.intimp.2017.08.019","volume":"52","author":"Q Lai","year":"2017","unstructured":"Lai Q, Luo Z, Wu C, et al. Attenuation of cyclosporine A induced nephrotoxicity by schisandrin B through suppression of oxidative stress, apoptosis and autophagy. Int Immunopharmacol. 2017;52:15\u201323.","journal-title":"Int Immunopharmacol"},{"issue":"6","key":"714_CR8","doi-asserted-by":"publisher","first-page":"513","DOI":"10.2174\/1389200219666180129151948","volume":"19","author":"M Yu","year":"2018","unstructured":"Yu M, Liu M, Zhang W, et al. Pharmacokinetics, pharmacodynamics and pharmacogenetics of tacrolimus in kidney transplantation. Curr Drug Metab. 2018;19(6):513\u201322.","journal-title":"Curr Drug Metab"},{"issue":"3","key":"714_CR9","doi-asserted-by":"publisher","first-page":"250","DOI":"10.4103\/1319-2442.393998","volume":"34","author":"N Alotaibi","year":"2023","unstructured":"Alotaibi N. CYP3A5 polymorphisms leading to tacrolimus toxicity following an adult renal transplant. Saudi J Kidney Dis Transpl. 2023;34(3):250\u20133.","journal-title":"Saudi J Kidney Dis Transpl"},{"issue":"4","key":"714_CR10","doi-asserted-by":"publisher","first-page":"880","DOI":"10.3906\/sag-1707-44","volume":"48","author":"J Li","year":"2018","unstructured":"Li J, Li H, Li Q, et al. Repaglinide inhibits cyclosporine A-induced renal tubular toxicity by affecting apoptosis and Bax and Bcl-2 expression. Turk J Med Sci. 2018;48(4):880\u20135.","journal-title":"Turk J Med Sci"},{"issue":"1","key":"714_CR11","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1007\/s11033-024-09533-2","volume":"51","author":"ME Nady","year":"2024","unstructured":"Nady ME, El-Raouf OMA, El-Sayed EM. Linagliptin ameliorates tacrolimus-induced renal injury: role of Nrf2\/HO-1 and HIF-1\u03b1\/CTGF\/PAI-1. Mol Biol Rep. 2024;51(1):608.","journal-title":"Mol Biol Rep"},{"issue":"10","key":"714_CR12","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.17219\/acem\/104544","volume":"28","author":"M Olukman","year":"2019","unstructured":"Olukman M, Can C, Co\u015fkunsever D, et al. Urotensin receptor antagonist Palosuran attenuates cyclosporine-a-induced nephrotoxicity in rats. Adv Clin Exp Med. 2019;28(10):1393\u2013401.","journal-title":"Adv Clin Exp Med"},{"issue":"3","key":"714_CR13","doi-asserted-by":"publisher","first-page":"101589","DOI":"10.1016\/j.jbc.2022.101589","volume":"298","author":"DE Yilmaz","year":"2022","unstructured":"Yilmaz DE, Kirschner K, Demirci H, et al. Immunosuppressive calcineurin inhibitor cyclosporine A induces proapoptotic Endoplasmic reticulum stress in renal tubular cells. J Biol Chem. 2022;298(3):101589.","journal-title":"J Biol Chem"},{"issue":"1","key":"714_CR14","doi-asserted-by":"publisher","first-page":"19555","DOI":"10.1038\/s41598-022-23834-1","volume":"12","author":"Y Yin","year":"2022","unstructured":"Yin Y, Shu Y, Zhu J, et al. A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for osimertinib. Sci Rep. 2022;12(1):19555.","journal-title":"Sci Rep"},{"issue":"1","key":"714_CR15","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","volume":"11","author":"EP van Puijenbroek","year":"2002","unstructured":"van Puijenbroek EP, Bate A, Leufkens HG, et al. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf. 2002;11(1):3\u201310.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"714_CR16","doi-asserted-by":"crossref","unstructured":"Aliabadi T, Saberi EA, Motameni Tabatabaei A, et al. Antibiotic use in endodontic treatment during pregnancy: A narrative review. Eur J Transl Myol. 2022;32(4):10813.","DOI":"10.4081\/ejtm.2022.10813"},{"issue":"4","key":"714_CR17","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s40264-016-0499-5","volume":"40","author":"ZA Trippe","year":"2017","unstructured":"Trippe ZA, Brendani B, Meier C, et al. Identification of substandard medicines via disproportionality analysis of individual case safety reports. Drug Saf. 2017;40(4):293\u2013303.","journal-title":"Drug Saf"},{"issue":"1","key":"714_CR18","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.jhep.2023.08.031","volume":"80","author":"F \u00c5berg","year":"2024","unstructured":"\u00c5berg F, Sallinen V, Tuominen S, et al. Cyclosporine vs. tacrolimus after liver transplantation for primary sclerosing cholangitis - a propensity score-matched intention-to-treat analysis. J Hepatol. 2024;80(1):99\u2013108.","journal-title":"J Hepatol"},{"issue":"5","key":"714_CR19","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1093\/ndt\/gfh739","volume":"20","author":"BK Kr\u00e4mer","year":"2005","unstructured":"Kr\u00e4mer BK, Montagnino G, Del Castillo D, et al. Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results. Nephrol Dial Transpl. 2005;20(5):968\u201373.","journal-title":"Nephrol Dial Transpl"},{"issue":"2","key":"714_CR20","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1097\/FTD.0000000000001014","volume":"45","author":"F Lemaitre","year":"2023","unstructured":"Lemaitre F, Budde K, Van Gelder T, et al. Therapeutic drug monitoring and dosage adjustments of immunosuppressive drugs when combined with Nirmatrelvir\/Ritonavir in patients with COVID-19. Ther Drug Monit. 2023;45(2):191\u20139.","journal-title":"Ther Drug Monit"},{"issue":"4","key":"714_CR21","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1093\/ndt\/gfq548","volume":"26","author":"F Brinkert","year":"2011","unstructured":"Brinkert F, Kemper MJ, Briem-Richter A, et al. High prevalence of renal dysfunction in children after liver transplantation: non-invasive diagnosis using a Cystatin C-based equation. Nephrol Dial Transpl. 2011;26(4):1407\u201312.","journal-title":"Nephrol Dial Transpl"},{"issue":"1","key":"714_CR22","doi-asserted-by":"publisher","first-page":"300060522114987","DOI":"10.1177\/03000605221149870","volume":"51","author":"X Li","year":"2023","unstructured":"Li X, Zhu W, Bao J, et al. Efficacy and safety of cyclosporine-based regimens for primary immune thrombocytopenia: a systematic review and meta-analysis. J Int Med Res. 2023;51(1):3000605221149870.","journal-title":"J Int Med Res"},{"issue":"12","key":"714_CR23","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1002\/acr.20609","volume":"63","author":"EM Camacho","year":"2011","unstructured":"Camacho EM, Verstappen SM, Lunt M, et al. Influence of age and sex on functional outcome over time in a cohort of patients with recent-onset inflammatory polyarthritis: results from the Norfolk arthritis register. Arthritis Care Res (Hoboken). 2011;63(12):1745\u201352.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"10055","key":"714_CR24","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","volume":"388","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023\u201338.","journal-title":"Lancet"},{"issue":"8","key":"714_CR25","first-page":"1516","volume":"33","author":"F Wolfe","year":"2006","unstructured":"Wolfe F, Michaud K. Anemia and renal function in patients with rheumatoid arthritis. J Rheumatol. 2006;33(8):1516\u201322.","journal-title":"J Rheumatol"},{"issue":"2","key":"714_CR26","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1111\/aor.13551","volume":"44","author":"Y Bentata","year":"2020","unstructured":"Bentata Y, Tacrolimus. 20 Years of use in adult kidney transplantation. What we should know about its nephrotoxicity. Artif Organs. 2020;44(2):140\u201352.","journal-title":"Artif Organs"},{"issue":"3","key":"714_CR27","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/s10528-017-9795-8","volume":"55","author":"A Ito","year":"2017","unstructured":"Ito A, Okada Y, Hashita T, et al. Sex differences in the blood concentration of tacrolimus in systemic lupus erythematosus and rheumatoid arthritis patients with CYP3A5*3\/*3. Biochem Genet. 2017;55(3):268\u201377.","journal-title":"Biochem Genet"},{"issue":"2","key":"714_CR28","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.gene.2012.10.048","volume":"512","author":"Y Shi","year":"2013","unstructured":"Shi Y, Li Y, Tang J, et al. Influence of CYP3A4, CYP3A5 and MDR-1 polymorphisms on tacrolimus pharmacokinetics and early renal dysfunction in liver transplant recipients. Gene. 2013;512(2):226\u201331.","journal-title":"Gene"},{"issue":"1","key":"714_CR29","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/tpj.2014.38","volume":"15","author":"L Rojas","year":"2015","unstructured":"Rojas L, Neumann I, Herrero MJ, et al. Effect of CYP3A5*3 on kidney transplant recipients treated with tacrolimus: a systematic review and meta-analysis of observational studies. Pharmacogenomics J. 2015;15(1):38\u201348.","journal-title":"Pharmacogenomics J"},{"key":"714_CR30","doi-asserted-by":"crossref","unstructured":"Lee FY, Islahudin F, Ali Nasiruddin AY, et al. Effects of CYP3A5 polymorphism on rapid progression of chronic kidney disease: A prospective, multicentre study. J Pers Med. 2021;11(4):252.","DOI":"10.3390\/jpm11040252"},{"issue":"5","key":"714_CR31","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1097\/00007890-200203150-00021","volume":"73","author":"F Vincenti","year":"2002","unstructured":"Vincenti F, Jensik SC, Filo RS, et al. A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years. Transplantation. 2002;73(5):775\u201382.","journal-title":"Transplantation"},{"issue":"5","key":"714_CR32","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1016\/S0041-1345(03)00642-0","volume":"35","author":"JM Moreno","year":"2003","unstructured":"Moreno JM, Cuervas-Mons V, Rubio E, et al. Chronic renal dysfunction after liver transplantation in adult patients: prevalence, risk factors, and impact on mortality. Transplant Proc. 2003;35(5):1907\u20138.","journal-title":"Transplant Proc."},{"issue":"12","key":"714_CR33","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1007\/s00228-024-03750-1","volume":"80","author":"HA Suilik","year":"2024","unstructured":"Suilik HA, Al-Shammari AS, Soliman Y, et al. Efficacy of tacrolimus versus cyclosporine after lung transplantation: an updated systematic review, meta-analysis, and trial sequential analysis of randomized controlled trials. Eur J Clin Pharmacol. 2024;80(12):1923\u201335.","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"714_CR34","doi-asserted-by":"publisher","first-page":"697","DOI":"10.5500\/wjt.v6.i4.697","volume":"6","author":"M Kamel","year":"2016","unstructured":"Kamel M, Kadian M, Srinivas T, et al. Tacrolimus confers lower acute rejection rates and better renal allograft survival compared to cyclosporine. World J Transpl. 2016;6(4):697\u2013702.","journal-title":"World J Transpl"},{"issue":"8","key":"714_CR35","doi-asserted-by":"publisher","first-page":"e14190","DOI":"10.1111\/apha.14190","volume":"240","author":"H Demirci","year":"2024","unstructured":"Demirci H, Popovic S, Dittmayer C, et al. Immunosuppression with cyclosporine versus tacrolimus shows distinctive nephrotoxicity profiles within renal compartments. Acta Physiol (Oxf). 2024;240(8):e14190.","journal-title":"Acta Physiol (Oxf)"},{"key":"714_CR36","doi-asserted-by":"crossref","unstructured":"Nishida S, Ishima T, Kimura N, et al. Metabolomic profiling of mice with Tacrolimus-Induced nephrotoxicity: carnitine deficiency in renal tissue. Biomedicines. 2024;12(3):521.","DOI":"10.3390\/biomedicines12030521"},{"key":"714_CR37","doi-asserted-by":"publisher","first-page":"153544","DOI":"10.1016\/j.tox.2023.153544","volume":"492","author":"J Yu","year":"2023","unstructured":"Yu J, Wei X, Gao J, et al. Role of cyclosporin A in the treatment of kidney disease and nephrotoxicity. Toxicology. 2023;492:153544.","journal-title":"Toxicology"},{"issue":"2","key":"714_CR38","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1093\/ndt\/gfl608","volume":"22","author":"AK Khanna","year":"2007","unstructured":"Khanna AK, Pieper GM. NADPH oxidase subunits (NOX-1, p22phox, Rac-1) and tacrolimus-induced nephrotoxicity in a rat renal transplant model. Nephrol Dial Transpl. 2007;22(2):376\u201385.","journal-title":"Nephrol Dial Transpl"},{"issue":"1","key":"714_CR39","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1177\/1553350610381088","volume":"18","author":"C Ara","year":"2011","unstructured":"Ara C, Dirican A, Unal B, et al. The effect of melatonin against FK506-induced renal oxidative stress in rats. Surg Innov. 2011;18(1):34\u20138.","journal-title":"Surg Innov"},{"key":"714_CR40","doi-asserted-by":"crossref","unstructured":"Park C, Kwon DH, Hwang SJ, et al. Protective effects of Nargenicin A1 against Tacrolimus-Induced oxidative stress in Hirame natural embryo cells. Int J Environ Res Public Health. 2019;16(6):1044.","DOI":"10.3390\/ijerph16061044"},{"issue":"2","key":"714_CR41","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/j.1742-7843.2006.pto_284.x","volume":"98","author":"F Hisamura","year":"2006","unstructured":"Hisamura F, Kojima-Yuasa A, Kennedy DO, et al. Protective effect of green tea extract and tea polyphenols against FK506-induced cytotoxicity in renal cells. Basic Clin Pharmacol Toxicol. 2006;98(2):192\u20136.","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"714_CR42","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.mito.2022.08.004","volume":"66","author":"N Dagar","year":"2022","unstructured":"Dagar N, Kale A, Steiger S, et al. Receptor-mediated mitophagy: an emerging therapeutic target in acute kidney injury. Mitochondrion. 2022;66:82\u201391.","journal-title":"Mitochondrion"},{"issue":"2","key":"714_CR43","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/S0272-6386(99)70299-4","volume":"33","author":"A Fassi","year":"1999","unstructured":"Fassi A, Sangalli F, Colombi F, et al. Beneficial effects of calcium channel Blockade on acute glomerular hemodynamic changes induced by cyclosporine. Am J Kidney Dis. 1999;33(2):267\u201375.","journal-title":"Am J Kidney Dis"},{"key":"714_CR44","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/1755-1536-7-15","volume":"7","author":"X Li","year":"2014","unstructured":"Li X, Zhuang S. Recent advances in renal interstitial fibrosis and tubular atrophy after kidney transplantation. Fibrogenesis Tissue Repair. 2014;7:15.","journal-title":"Fibrogenesis Tissue Repair"},{"issue":"3","key":"714_CR45","doi-asserted-by":"publisher","first-page":"F489","DOI":"10.1152\/ajprenal.00575.2016","volume":"312","author":"KI Blankenstein","year":"2017","unstructured":"Blankenstein KI, Borschewski A, Labes R, et al. Calcineurin inhibitor cyclosporine A activates renal Na-K-Cl cotransporters via local and systemic mechanisms. Am J Physiol Ren Physiol. 2017;312(3):F489\u2013501.","journal-title":"Am J Physiol Ren Physiol"},{"issue":"10","key":"714_CR46","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1038\/nm.2497","volume":"17","author":"EJ Hoorn","year":"2011","unstructured":"Hoorn EJ, Walsh SB, McCormick JA, et al. The calcineurin inhibitor tacrolimus activates the renal sodium chloride cotransporter to cause hypertension. Nat Med. 2011;17(10):1304\u20139.","journal-title":"Nat Med"},{"issue":"1","key":"714_CR47","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s12958-020-00658-0","volume":"18","author":"B He","year":"2020","unstructured":"He B, Li QY, Wu YY, et al. Cyclosporin A protects JEG-3 cells against oxidative stress-induced apoptosis by inhibiting the p53 and JNK\/p38 signaling pathways. Reprod Biol Endocrinol. 2020;18(1):100.","journal-title":"Reprod Biol Endocrinol"},{"issue":"3","key":"714_CR48","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1097\/FTD.0000000000000640","volume":"41","author":"M Brunet","year":"2019","unstructured":"Brunet M, van Gelder T, \u00c5sberg A, et al. Therapeutic drug monitoring of Tacrolimus-Personalized therapy: second consensus report. Ther Drug Monit. 2019;41(3):261\u2013307.","journal-title":"Ther Drug Monit"},{"issue":"3","key":"714_CR49","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1097\/TP.0000000000003350","volume":"105","author":"SC Ong","year":"2021","unstructured":"Ong SC, Gaston RS. Thirty years of tacrolimus in clinical practice. Transplantation. 2021;105(3):484\u201395.","journal-title":"Transplantation"},{"issue":"2","key":"714_CR50","doi-asserted-by":"publisher","first-page":"84","DOI":"10.2174\/1389200219666181031113505","volume":"20","author":"Q Wu","year":"2019","unstructured":"Wu Q, Kuca K. Metabolic pathway of cyclosporine A and its correlation with nephrotoxicity. Curr Drug Metab. 2019;20(2):84\u201390.","journal-title":"Curr Drug Metab"},{"issue":"6","key":"714_CR51","doi-asserted-by":"publisher","first-page":"466","DOI":"10.5414\/CP201836","volume":"51","author":"DY Li","year":"2013","unstructured":"Li DY, Teng RC, Zhu HJ, et al. CYP3A4\/5 polymorphisms affect the blood level of cyclosporine and tacrolimus in Chinese renal transplant recipients. Int J Clin Pharmacol Ther. 2013;51(6):466\u201374.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"15","key":"714_CR52","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.2217\/pgs-2019-0090","volume":"20","author":"L Huang","year":"2019","unstructured":"Huang L, Wang J, Yang J, et al. Impact of CYP3A4\/5 and ABCB1 polymorphisms on tacrolimus exposure and response in pediatric primary nephrotic syndrome. Pharmacogenomics. 2019;20(15):1071\u201383.","journal-title":"Pharmacogenomics"},{"key":"714_CR53","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3390\/jcm11216320","volume":"11","author":"A Nuchjumroon","year":"2022","unstructured":"Nuchjumroon A, Vadcharavivad S, Singhan W, et al. Comparison of tacrolimus Intra-Patient variability during 6\u201312 months after kidney transplantation between CYP3A5 expressers and nonexpressers. J Clin Med. 2022;11:21.","journal-title":"J Clin Med"},{"issue":"5","key":"714_CR54","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1097\/FPC.0b013e328351f3c1","volume":"22","author":"L Elens","year":"2012","unstructured":"Elens L, Bouamar R, Hesselink DA, et al. The new CYP3A4 intron 6 C\u2009>\u2009T polymorphism (CYP3A4*22) is associated with an increased risk of delayed graft function and worse renal function in cyclosporine-treated kidney transplant patients. Pharmacogenet Genomics. 2012;22(5):373\u201380.","journal-title":"Pharmacogenet Genomics"},{"issue":"11","key":"714_CR55","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1111\/cts.13639","volume":"16","author":"G Ciancio","year":"2023","unstructured":"Ciancio G, Gaynor JJ, Guerra G, et al. Long-term effects of average calcineurin inhibitor trough levels (over time) on renal function in a prospectively followed cohort of 150 kidney transplant recipients. Clin Transl Sci. 2023;16(11):2382\u201393.","journal-title":"Clin Transl Sci"},{"issue":"3","key":"714_CR56","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/clpt.2012.109","volume":"92","author":"H de Jonge","year":"2012","unstructured":"de Jonge H, de Loor H, Verbeke K, et al. In vivo CYP3A4 activity, CYP3A5 genotype, and hematocrit predict tacrolimus dose requirements and clearance in renal transplant patients. Clin Pharmacol Ther. 2012;92(3):366\u201375.","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"714_CR57","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1097\/00007890-199610150-00005","volume":"62","author":"DA Laskow","year":"1996","unstructured":"Laskow DA, Vincenti F, Neylan JF, et al. An open-label, concentration-ranging trial of FK506 in primary kidney transplantation: a report of the united States multicenter FK506 kidney transplant group. Transplantation. 1996;62(7):900\u20135.","journal-title":"Transplantation"}],"container-title":["BMC Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12865-025-00714-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12865-025-00714-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12865-025-00714-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T13:27:47Z","timestamp":1746192467000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcimmunol.biomedcentral.com\/articles\/10.1186\/s12865-025-00714-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,2]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["714"],"URL":"https:\/\/doi.org\/10.1186\/s12865-025-00714-7","relation":{},"ISSN":["1471-2172"],"issn-type":[{"value":"1471-2172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,2]]},"assertion":[{"value":"30 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"35"}}